SIGYSigyn Therapeutics Inc.

About Sigyn Therapeutics Inc. (SIGY)

Sigyn Therapeutics Inc. (SIGY) is a Biotechnology company headquartered in San Diego, CA, United States whose shares trade over-the-counter on the OTCQB tier.

Sigyn Therapeutics is a development-stage medical technology company headquartered in San Diego, California. Sigyn Therapeutics develops blood purification devices to treat cancer and life-threatening infections. Our therapeutic candidates include the ImmunePrepTM platform to optimize the delivery of immunotherapeutic antibodies (best selling drugs to treat cancer); ChemoPrepTM to improve the delivery of chemotherapy (most commonly administered drug to treat cancer); ChemoPureTM to mitigate the toxicity of chemotherapy; and Sigyn TherapyTM to address life-threatening infections. Based on results from preclinical and first-in-mammal studies, human feasibility studies of Sigyn Therapy plan to enroll end-stage renal disease (ESRD) subjects with endotoxemia, which is a highly prevalent condition in dialysis patients. Other therapeutic opportunities include the treatment of viruses that are not addressed with drugs, antibiotic-resistant bacterial infections, and sepsis, the leading cause of hospital deaths in the United States.

Products and services

Sigyn Therapeutics is a developer of blood purification technologies to treat cancer and life-threatening infections. Our therapeutic candidates include the ImmunePrepTM platform to improve the delivery of immunotherapeutic antibodies; ChemoPrepTM to improve the delivery of chemotherapy; ChemoPureTM to mitigate the toxicity of chemotherapy; and Sigyn TherapyTM to treat life-threatening infections.

SIGY key facts

Ticker symbol

SIGY

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

San Diego, CA, United States

Country of incorporation

US

Year of incorporation

2014

Employees

5

Estimated market cap

$5.67M (as of May 14, 2025)

Shares outstanding

1,605,377

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Sigyn Therapeutics Inc. leadership

• James Allen Joyce — CEO, Interim CFO
• Gerald Albert Deciccio — Consultant

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with S